Tomorrow BioTech and The Super Crowd join forces to give biotech startups labs, crowdfunding, and capital to turn ...

In 2025 it seemed the only certainty for biotech was more uncertainty. Biotech leaders conducted business as usual against ...

Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of ...

Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics ...

The program, which launches in the fall, includes different pathways to be industry-ready, ranging from micro-credentials to a full associate degree. A $3 million lab modeled on real industry ...

Samsung Biologics has teamed up with Eli Lilly to set up an open innovation hub for emerging biotechnology companies in Korea, marking the first time for Eli Li ...

US biotech Vima Therapeutics has secured $40 million in a series A extension to support development of its oral movement-disorder therapy VIM0423, bringing the total financing round to $100 million.

"2025 proved that our technology delivers, not in the distant future, but right now," says Tropic CEO Gilad Gershon.

Rapid Micro Biosystems, Inc. sees strong FY25 revenue growth from Growth Direct placements, but losses persist. Click for more on RPID Q4 earnings results.

Strategic investment reinforces Europe as a core pillar of GenScript's global R&Dand production network, following recent U.S. facility expansion.

It’s no longer a question if these companies will grow; it’s about how and where they choose to grow to offer flexibility, manage risk and support long-term stability.